Effects of Multiple Doses of CS-8080 in Healthy Volunteers

A Randomized, Placebo-Controlled, Multiple Ascending Dose Study To Assess The Safety, Pharmacokinetics and Pharmacodynamics Of CS-8080 In Healthy Volunteers

The main purposes of this study are to assess the safety and measure the pharmacokinetics and pharmacodynamics of CS-8080 in healthy volunteers.

Study Overview

• Status: Terminated
• Conditions: Healthy
• Intervention / Treatment: Drug: CS-8080; Drug: CS-8080; Drug: CS-8080; Drug: placebo tablets

• Study Type: Interventional
• Enrollment (Actual): 16
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • New Jersey
    • Neptune, New Jersey, United States, 07753
      • MDS Pharma Services

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Healthy men and/or women, aged 18 to 45 years inclusive.
• WOCBP cannot be pregnant or nursing, must have been using a medically acceptable method of contraception for at least 3 months prior to study screening
• All women must have a negative quantitative serum pregnancy test at screening, on Day -4, and within 24 hours before dosing.
• Male subjects must agree not to donate sperm during the study and for 3 months after their last scheduled visit. Males must also agree to use a use a condom with spermicide whenever engaging in sexual activity for this period of time.
• Body Mass Index (BMI) of 19 to 30 kg/m inclusive and weight <300 lbs.
• Good health as determined by the absence of clinically significant deviation from normal, based on medical history, physical examination, laboratory reports, and 12-lead ECG, as deemed by the Investigator, prior to enrollment.
• Able to understand and willing to comply with all study requirements, and willing to follow the study medication regimen.
• Willing and able to give a written informed consent.
• Negative urine test for drugs of abuse and alcohol at screening and check-in.
• Negative result for HIV antibody, hepatitis B surface antigen, and hepatitis C antibody at screening.
• Subjects must agree not to donate blood, plasma, platelets, or any other blood components during the study and for 4 weeks after the last dose.

Exclusion Criteria:

• WOCBP is pregnant (as based on test results) or is breast feeding.
• Subject is not using adequate contraceptive precautions.
• Any history of drug abuse.
• History of alcohol addiction during the 2 years prior to Day 1.
• History of significant allergic response to any drug except penicillin, or known sensitivity to any of the products to be administered during dosing.
• History or current evidence, as determined by the Investigator, of psychiatric or emotional problems which would invalidate giving informed consent or limit the ability of the subject to comply with study requirements.
• History or current evidence of clinically significant cardiac, hepatic, renal, pulmonary, endocrine, neurologic, infectious, gastrointestinal (ie, any condition which may affect drug absorption), hematologic, or oncologic disease as determined by the Investigator after reviewing screening history, physical examination, laboratory test results, and 12-lead ECG.
• History or current alcoholic or non-alcoholic liver disease or liver steatosis.
• History of prostate disease or prostatitis.
• Subjects with a history of congenital Long QT Syndrome (LQTS), a history of surviving a near-drowning episode, or a history of any form of syncope or loss of consciousness.
• Subjects with QTcF interval duration >450 msec obtained as an average from the ECG machine readings on the triplicate ECG (3 readings not more than 2 minutes apart) taken at screening, after at least 10 minutes of quiet rest in a supine position.
• Subjects with abnormal ECG waveform morphology on any of the ECGs from the screening triplicate that would preclude accurate manual measurement of the QT interval duration.
• Need for any concomitant medication.
• Prestudy medication use as specified in protocol.
• Consumption of any food or beverages containing grapefruit from 7 days prior to Day 1 through study completion.
• Consumption of foods or beverages containing alcohol from 24 hours before check-in through discharge from the clinic.
• Blood donation or significant blood loss within the 56 days before Day -1.
• Plasma donation within 7 days before Day -1.
• Participation in another investigational new drug research study within the 30 days before Day 1.
• Prior exposure to CS-8080.
• Use of tobacco products or nicotine-containing products (including smoking cessation aids, such as gums or patches) within the 6 months before Day 1.
• Relationship of the subject to the Investigator, any sub-investigator, pharmacist, study coordinator, or other staff directly involved in the conduct of the study, or employment by the Sponsor or contract research organization participating in the study.
• Familial relationship with any other study participant.
• Screening laboratory values outside the range of normal values deemed clinically significant by the Investigator. Serum lipid tests, triglycerides, cholesterol (LDL, HDL and total cholesterol), liver function tests (ALT, AST, GGT, total bilirubin, LDH and ALP) and PSA must not exceed the upper limit of normal without permission of the Sponsor. For males, testosterone, LH and FSH must be within normal limits.
• Hemoglobin <12.0 g/dL at the screening visit.
• Positive fecal occult blood test at screening.
• Shift work, defined as any work shifts, either regular or irregular, precluding sleep during the hours of 10 pm and 6 am, within 1 week prior to Day -4, and no more than 2 works shifts per week meeting the above criteria from 4 to 1 week prior to Day -4.
• Any of the following, if determined to render the subject ineligible for hepatic MRI scanning: pacemaker, aneurism clips, heart valve replacements, cochlear implants, neuro- or spine-stimulator, pessary (bladder support), body piercing that cannot be removed, metal slivers in eyes, shrapnel, hearing aid that cannot be removed, non-removable metal dental work or dentures, tattoos over 20 years old, IUD or penile implant. An X-ray may be required to assess eligibilty for the procedure.
• History of claustrophobia or intolerance to MRI scanning procedures.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: DOUBLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
PLACEBO_COMPARATOR: placebo	Drug: placebo tablets; placebo tablets matching active
EXPERIMENTAL: CS-8080; 3 mg CS-8080, 10mg CS-8080, 20 mg CS-8080	Drug: CS-8080; CS-8080 1mg tablets, 3 tablets administered 1 times per day; Drug: CS-8080; CS-8080 5 mg tablets, 2 tablets administered 1 times per day; Drug: CS-8080; CS-8080 5 mg tablets, 4 tablets administered 1 times per day

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Safety	21 days
plasma pharmacokinetics after multiple doses	16 days
effect on ABCA1 mRNA after multiple doses	16 days
effect on ABCG1 mRNA after multiple doses	16 days

Secondary Outcome Measures

Outcome Measure	Time Frame
effect on gene expression by microarray after multiple doses	16 days
effect on triglycerides following an oral fat load after multiple doses	16 days
effect on plasma lipids after multiple doses	16 days
effect on lipoproteins after multiple doses	16 days
effect on HDL particle distribution after multiple doses	16 days
effect on hepatic fat content after multiple doses	16 days

Collaborators and Investigators

• Sponsor: Daiichi Sankyo, Inc.

Study record dates

Study Major Dates

• Study Start: November 1, 2008
• Primary Completion (ACTUAL): December 1, 2008
• Study Completion (ACTUAL): December 1, 2008

Study Registration Dates

• First Submitted: November 21, 2008
• First Submitted That Met QC Criteria: November 21, 2008
• First Posted (ESTIMATE): November 24, 2008

Study Record Updates

• Last Update Posted (ACTUAL): December 21, 2018
• Last Update Submitted That Met QC Criteria: December 19, 2018
• Last Verified: April 1, 2015

More Information

Terms related to this study

• Keywords: pharmacokinetics; pharmacodynamics; multiple ascending dose healthy volunteers
• Other Study ID Numbers: CS8080-A-U102

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
• IPD Sharing Time Frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
• IPD Sharing Access Criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ANALYTIC_CODE; CSR